FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149506592> ?p ?o ?g. }

• W2149506592 endingPage "1087" @default.
• W2149506592 startingPage "1081" @default.
• W2149506592 abstract "The potential combined effect and mechanism of calcium channel blockers (CCB) and angiotensin II type 1 receptor blockers (ARB) to improve insulin resistance were investigated in type 2 diabetic KK-Ay mice, focusing on their antioxidative action. Treatment of KK-Ay mice with a CCB, azelnidipine (3 mg/kg/day), or with an ARB, olmesartan (3 mg/kg/day), for 2 weeks lowered the plasma concentrations of glucose and insulin in the fed state, attenuated the increase in plasma glucose in the oral glucose tolerance test (OGTT), and increased 2-[³H]deoxy-d-glucose (2-[³H]DG) uptake into skeletal muscle with the increase in translocation of glucose transporter 4 (GLUT4) to the plasma membrane. Both blockers also decreased the in situ superoxide production in skeletal muscle. The decrease in plasma concentrations of glucose and insulin in the fed state and superoxide production in skeletal muscle, as well as GLUT4 translocation to the plasma membrane, after azelnidipine administration was not significantly affected by coadministration of an antioxidant, 2,2,6,6-tetramethyl-1-piperidinyloxy (tempol). However, those changes caused by olmesartan were further improved by tempol. Moreover, olmesartan enhanced the insulin-induced tyrosine phosphorylation of insulin receptor substrate-1 induced in skeletal muscle, whereas azelnidipine did not change it. Coadministration of azelnidipine and olmesartan further decreased the plasma concentrations of glucose and insulin, improved OGTT, and increased 2-[³H]DG uptake in skeletal muscle. These results suggest that azelnidipine improved glucose intolerance mainly through inhibition of oxidative stress and enhanced the inhibitory effects of olmesartan on glucose intolerance, as well as the clinical possibility that the combination of CCB and ARB could be more effective than monotherapy in the treatment of insulin resistance." @default.
• W2149506592 created "2016-06-24" @default.
• W2149506592 creator A5001563356 @default.
• W2149506592 creator A5011935809 @default.
• W2149506592 creator A5015686941 @default.
• W2149506592 creator A5029101744 @default.
• W2149506592 creator A5033712820 @default.
• W2149506592 creator A5042806847 @default.
• W2149506592 creator A5053453125 @default.
• W2149506592 creator A5062279697 @default.
• W2149506592 creator A5073179935 @default.
• W2149506592 creator A5083595001 @default.
• W2149506592 creator A5083720055 @default.
• W2149506592 creator A5087284224 @default.
• W2149506592 creator A5073901014 @default.
• W2149506592 date "2006-09-21" @default.
• W2149506592 modified "2023-09-27" @default.
• W2149506592 title "Calcium Channel Blocker Azelnidipine Reduces Glucose Intolerance in Diabetic Mice via Different Mechanism Than Angiotensin Receptor Blocker Olmesartan" @default.
• W2149506592 cites W186790523 @default.
• W2149506592 cites W1966752541 @default.
• W2149506592 cites W1972866300 @default.
• W2149506592 cites W1974548284 @default.
• W2149506592 cites W1984633752 @default.
• W2149506592 cites W1993340561 @default.
• W2149506592 cites W2030338284 @default.
• W2149506592 cites W2030415436 @default.
• W2149506592 cites W2064384952 @default.
• W2149506592 cites W2067942918 @default.
• W2149506592 cites W2073353638 @default.
• W2149506592 cites W2087559174 @default.
• W2149506592 cites W2093034072 @default.
• W2149506592 cites W2107446346 @default.
• W2149506592 cites W2108132451 @default.
• W2149506592 cites W2119869567 @default.
• W2149506592 cites W2124610904 @default.
• W2149506592 cites W2126620184 @default.
• W2149506592 cites W2142834180 @default.
• W2149506592 cites W2143977823 @default.
• W2149506592 cites W2146960356 @default.
• W2149506592 cites W2148637873 @default.
• W2149506592 cites W2156783035 @default.
• W2149506592 cites W2157363415 @default.
• W2149506592 cites W2163833854 @default.
• W2149506592 cites W2168276527 @default.
• W2149506592 cites W2168975002 @default.
• W2149506592 cites W2171157803 @default.
• W2149506592 cites W2171496171 @default.
• W2149506592 cites W2319890530 @default.
• W2149506592 doi "https://doi.org/10.1124/jpet.106.108894" @default.
• W2149506592 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16990512" @default.
• W2149506592 hasPublicationYear "2006" @default.
• W2149506592 type Work @default.
• W2149506592 sameAs 2149506592 @default.
• W2149506592 citedByCount "34" @default.
• W2149506592 countsByYear W21495065922012 @default.
• W2149506592 countsByYear W21495065922013 @default.
• W2149506592 countsByYear W21495065922014 @default.
• W2149506592 countsByYear W21495065922015 @default.
• W2149506592 countsByYear W21495065922017 @default.
• W2149506592 countsByYear W21495065922018 @default.
• W2149506592 countsByYear W21495065922019 @default.
• W2149506592 countsByYear W21495065922021 @default.
• W2149506592 countsByYear W21495065922023 @default.
• W2149506592 crossrefType "journal-article" @default.
• W2149506592 hasAuthorship W2149506592A5001563356 @default.
• W2149506592 hasAuthorship W2149506592A5011935809 @default.
• W2149506592 hasAuthorship W2149506592A5015686941 @default.
• W2149506592 hasAuthorship W2149506592A5029101744 @default.
• W2149506592 hasAuthorship W2149506592A5033712820 @default.
• W2149506592 hasAuthorship W2149506592A5042806847 @default.
• W2149506592 hasAuthorship W2149506592A5053453125 @default.
• W2149506592 hasAuthorship W2149506592A5062279697 @default.
• W2149506592 hasAuthorship W2149506592A5073179935 @default.
• W2149506592 hasAuthorship W2149506592A5073901014 @default.
• W2149506592 hasAuthorship W2149506592A5083595001 @default.
• W2149506592 hasAuthorship W2149506592A5083720055 @default.
• W2149506592 hasAuthorship W2149506592A5087284224 @default.
• W2149506592 hasConcept C104849204 @default.
• W2149506592 hasConcept C126322002 @default.
• W2149506592 hasConcept C134018914 @default.
• W2149506592 hasConcept C161573976 @default.
• W2149506592 hasConcept C170493617 @default.
• W2149506592 hasConcept C185592680 @default.
• W2149506592 hasConcept C2776188179 @default.
• W2149506592 hasConcept C2777866211 @default.
• W2149506592 hasConcept C2779306644 @default.
• W2149506592 hasConcept C2779766728 @default.
• W2149506592 hasConcept C2779959927 @default.
• W2149506592 hasConcept C2780356492 @default.
• W2149506592 hasConcept C2908929049 @default.
• W2149506592 hasConcept C519063684 @default.
• W2149506592 hasConcept C71924100 @default.
• W2149506592 hasConcept C84393581 @default.
• W2149506592 hasConcept C98274493 @default.
• W2149506592 hasConceptScore W2149506592C104849204 @default.
• W2149506592 hasConceptScore W2149506592C126322002 @default.
• W2149506592 hasConceptScore W2149506592C134018914 @default.
• W2149506592 hasConceptScore W2149506592C161573976 @default.

• next